PBLA Key Statistics, Chart & Performance
The current stock price of PBLA is 1.11 USD. In the past month the price decreased by -7.5%. In the past year, price decreased by -99.73%.
PBLA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.7 | 412.54B | ||
| AMGN | AMGEN INC | 15.62 | 183.97B | ||
| GILD | GILEAD SCIENCES INC | 15.18 | 154.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.89 | 122.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 18.05 | 85.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 828.43 | 55.82B | ||
| INSM | INSMED INC | N/A | 37.54B | ||
| NTRA | NATERA INC | N/A | 35.11B | ||
| BIIB | BIOGEN INC | 11.17 | 27.42B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.09 | 21.69B | ||
| INCY | INCYTE CORP | 17.22 | 21.71B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.29B |
Related stock screener links
About PBLA
Company Profile
Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. The company is headquartered in Waconia, Minnesota and currently employs 6 full-time employees. The company went IPO on 2014-07-29. The firm is involved in enrolling patients in its randomized double-blind placebo-controlled clinical trial for the treatment of pancreatic cancer. The firm's lead assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X). Ivospemin is a polyamine analog designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumors. Flynpovi is a combination of CPP-1X (eflornithine) and sulindac with a dual mechanism inhibiting polyamine synthesis and increasing polyamine export and catabolism. Eflornithine is being developed as a single-agent tablet or high-dose powder sachet for several indications, including prevention of gastric cancer, treatment of neuroblastoma and recent onset Type 1 diabetes.
Company Info
PANBELA THERAPEUTICS INC
712 Vista Blvd # 305
Waconia MINNESOTA 55387 US
CEO: Jennifer K. Simpson
Employees: 6
Phone: 19524791196
PANBELA THERAPEUTICS INC / PBLA FAQ
What does PBLA do?
Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. The company is headquartered in Waconia, Minnesota and currently employs 6 full-time employees. The company went IPO on 2014-07-29. The firm is involved in enrolling patients in its randomized double-blind placebo-controlled clinical trial for the treatment of pancreatic cancer. The firm's lead assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X). Ivospemin is a polyamine analog designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumors. Flynpovi is a combination of CPP-1X (eflornithine) and sulindac with a dual mechanism inhibiting polyamine synthesis and increasing polyamine export and catabolism. Eflornithine is being developed as a single-agent tablet or high-dose powder sachet for several indications, including prevention of gastric cancer, treatment of neuroblastoma and recent onset Type 1 diabetes.
What is the stock price of PANBELA THERAPEUTICS INC today?
The current stock price of PBLA is 1.11 USD. The price decreased by -9.76% in the last trading session.
What is the dividend status of PANBELA THERAPEUTICS INC?
PBLA does not pay a dividend.
What is the ChartMill rating of PANBELA THERAPEUTICS INC stock?
PBLA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Where is PANBELA THERAPEUTICS INC (PBLA) stock traded?
PBLA stock is listed on the Nasdaq exchange.
Should I buy PBLA stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PBLA.
What is the market capitalization of PBLA stock?
PANBELA THERAPEUTICS INC (PBLA) has a market capitalization of 1.41M USD. This makes PBLA a Nano Cap stock.
PBLA Technical Analysis
PBLA Financial Highlights
Over the last trailing twelve months PBLA reported a non-GAAP Earnings per Share(EPS) of -4010.88. The EPS decreased by -67.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -221.35% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PBLA Forecast & Estimates
8 analysts have analysed PBLA and the average price target is 418.2 USD. This implies a price increase of 37575.68% is expected in the next year compared to the current price of 1.11.